

Sorafenib Tosylate (BAY43-9006 Tosylate)

Catalog No: tcsc0164



Available Sizes

Size: 100mg

Size: 500mg

Size: 1g

Size: 2g

Size: 5g

Size: 10g



Specifications

CAS No:

475207-59-1

Formula:

$C_{28}H_{24}ClF_3N_4O_6S$

Pathway:

Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Autophagy;Protein Tyrosine Kinase/RTK

Target:

VEGFR;Raf;FLT3;PDGFR;Autophagy;c-Kit

Purity / Grade:

>98%

Solubility:

H₂O :

Alternative Names:

Bay 43-9006

Observed Molecular Weight:

637.03


Product Description

Sorafenib tosylate is a potent multikinase inhibitor, with **IC₅₀**s of 6 nM, 20 nM, and 22 nM for **Raf-1**, **B-Raf**, and **VEGFR-3**, respectively.

IC50 & Target: IC50: 6 nM (Raf-1), 20 nM (VEGFR-3), 22 nM (BRAF), 57 nM (PDGFR-β), 58 nM (Flt3), 68 nM (c-KIT), 90 nM (VEGFR-2)^[1]

In Vitro: Sorafenib Tosylate also inhibits BRAF^{wt} (IC₅₀=22 nM), BRAF^{V599E} (IC₅₀=38 nM), VEGFR-2 (IC₅₀=90 nM), VEGFR-3 (IC₅₀=20 nM), PDGFR-β (IC₅₀=57 nM), c-KIT (IC₅₀=68 nM), and Flt3 (IC₅₀=58 nM) in biochemical assays^[1]. Sorafenib-induced phosphorylation of c-Met, p70S6K and 4EBP1 is significantly reduced when 10-0505 cells are co-treated with anti-human anti-HGF antibody, suggesting that treatment with Sorafenib Tosylate leads to increased HGF secretion and activation of c-Met and mTOR targets^[2].

In Vivo: Sorafenib Tosylate (10, 30, 50 and 100 mg/kg, orally) treatment inhibits the tumor growth of 06-0606 and 10-0505 xenografts in a dose-dependent manner (P[2]. The survival rate is 73.3 % in Diethyl nitrosamine (DENA) group and 83.3 % in Sorafenib group compared to 100 % in the normal control group. DENA group shows a significant increase in liver index (1.51-fold increase, p[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!